Medical treatment of intracranial arterial stenosis. Are primary and secondary prevention the same thing?;Tratamiento médico de la estenosis arterial intracraneal. ¿Es el mismo en prevención primaria que en secundaria?

Revista de Neurologia

Volumn 37, Issue 7, 2003, Pages 644-648

  Irimia Sieira, Pablo ^a   Riverol Fernandez M ^a   Martinez Vila E ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Antithrombotic drugs; Cerebral ischemia; Intracranial stenosis; Medical treatment; Prevention; Stroke

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

BRAIN ISCHEMIA; CEREBROVASCULAR DISEASE; DISEASE COURSE; HUMAN; POSITRON EMISSION TOMOGRAPHY; REVIEW; RISK FACTOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STROKE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS PREVENTION;

EID: 0242354165     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3707.2003410     Document Type: Review

References (43)

1. Sacco RL, Kargman DE, Gu Q, Zamanillo MC. Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study. Stroke 1995; 26: 14-20.
2. Caplan LR, Gorelick PB, Hier DB. Race, sex and occlusive cerebrovascular disease: a review. Stroke 1986; 17: 648-55.
3. Inzitari D, Hachinski VC, Taylor DW, Barnett HJ. Racial differences in the anterior circulation in cerebrovascular disease. How much can be explained by risk factors? Arch Neurol 1990; 47: 1080-4.
4. Ingall TJ, Homer D, Baker HL Jr, Kottke BA, O'Fallon WM, Whisnant JP. Predictors of intracranial carotid artery atherosclerosis. Duration of cigarette smoking and hypertension are more powerful than serum lipid levels. Arch Neurol 1991; 48: 687-91.
5. Wityk RJ, Lehman D, Klag M, Coresh J, Ahn H, Litt B. Race and sex differences in the distribution of cerebral atherosclerosis. Stroke 1996; 27: 1974-80.
6. Chimowitz MI, Kokkinos J, Strong J, Brown MB, Levine SR, Silliman S, et al. The Warfarin-Aspirin Symptomatic Intracranial Disease Study. Neurology 1995; 45: 1488-93.
7. Uehara T, Tabuchi M, Hayashi T, Kurogane H, Yamadori A. Asymptomatic occlusive lesions of carotid and intracranial arteries in Japanese patients with ischemic heart disease: evaluation by brain magnetic resonance angiography. Stroke 1996; 27: 393-7.
8. Akins PT, Pilgram TK, Cross DT III, Moran CJ. Natural history of stenosis from intracranial atherosclerosis by serial angiography. Stroke 1998; 29: 433-8.
9. Wong KS, Li H, Lam WW, Chan YL, Kay R. Progression of middle cerebral artery occlusive disease and its relationship with further vascular events after stroke. Stroke 2002; 33: 532-6.
10. Arenillas JF, Molina CA, Montaner J, Abilleira S, Gonzá lez-Sánchez MA, Álvarez-Sabin J. Progression and clinical recurrence of symptomatic middle cerebral artery stenosis: a long-term follow-up transcranial Doppler ultrasound study. Stroke 2001; 32: 2898-904.
11. Gómez CR, Orr SC. Angioplasty and stenting for primary treatment of intracranial arterial stenoses. Arch Neurol 2001; 58: 1687-90.
12. Segura T, Serena J, Castellanos M, Teruel J, Vilar C, Davalos A. Embolism in acute middle cerebral artery stenosis. Neurology 2001; 56: 497-501.
13. Lammie GA, Sandercock PA, Dennis MS. Recently occluded intracranial and extracranial carotid arteries. Relevance of the unstable atherosclerotic plaque. Stroke 1999; 30: 1319-25.
14. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992; 326: 310-8.
15. Moons AH, Levi M, Peters RJ. Tissue factor and coronary artery disease. Cardiovasc Res 2002; 53: 313-25.
16. Thijs VN, Albers GW. Symptomatic intracranial atherosclerosis: outcome of patients who fail antithrombotic therapy. Neurology 2000; 55: 490-7.
17. Lutsep HL, Clark WM. Association of intracranial stenosis with cortical symptoms or signs. Neurology 2000; 55: 716-8.
18. López-Bescos L, Fernández-Ortiz A, Bueno-Zamora H, Coma-Canella I, Lidon-Corbi RM, Cequier-Fillat A, et al. Guías de práctica clínica en la angina inestable/infarto sin elevación de ST. Rev Esp Cardiol 2000; 53: 838-50.
19. Furberg CD, Adams HP Jr, Applegate WB, Byington RP, Espeland MA, Hartwell T, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994; 90: 1679-87.
20. Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu C, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial. Ann Intern Med 1996; 124: 548-56.
21. White HD, Simes RJ, Anderson NE, Hankey GJ, Watson JD, Hunt D, et al. Pravastatin therapy and the risk of stroke. N Engl J Med 2000; 343: 317-26.
22. Crouse JR III, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995; 75: 455-9.
23. Hess DC, Demchuk AM, Brass LM, Yatsu FM. HMG-CoA reductase inhibitors (statins): a promising approach to stroke prevention. Neurology 2000; 54: 790-6.
24. Rosenson RS. Biological basis for statin therapy in stroke prevention. Curr Opin Neurol 2000; 13: 57-62.
25. Callahan AS III, Berger BL, Beuter MJ, Devlin TG. Possible short-term amelioration of basilar plaque by high-dose atorvastatin: use of reductase inhibitors for intracranial plaque stabilization. J Neuroimaging 2001; 11: 202-4.
26. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme-inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
27. Lonn E, Yusuf S, Dzavik V, Doris C, Yi Q, Smith S, et al. Effects of ramipril and vitamin E on atherosclerosis: The Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E (SECURE). Circulation 2001; 103: 919-25.
28. Steering Committee of the Physicians' Health Study Research Group. Final report of the ongoing physicians health study. N Engl J Med 1989; 321: 129-35.
29. Manson J, Stampfer M, Colditz G, Willett W, Rosner B. Speizer F, et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA 1991; 266: 521-7.
30. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of anti-platelet therapy, I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
31. Bousser M, Eschwege E, Haguenau M, Lefaucconnier J, Thibult N, Touboul D, et al. AICLA controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983; 14: 5-14.
32. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
33. Diener H, Cunha L, Forties C, Silvenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
34. Gent M, Blakely J, Easton D, Ellis D, Hachinski W, Harbisson J, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215-20.
35. Millikan CK, Siekert RG, Shick RM. Studies in cerebrovascular disease: III. The use of anticoagulant drugs in the treatment of insufficiency or thrombosis within the basilar arterial system. Mayo Clin Proc 1955; 30: 116-26.
36. Buren A, Ygge J. Treatment program and comparison between anticoagulants and platelet antiaggregation inhibitors after transient ischemic attacks. Stroke 1981; 12: 578-80.
37. The EC/IC Bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial. N Engl J Med 1985; 313: 1191-200.
38. Kuhnen J, Steinke W, Kern R, Artemis N, Hennerici M. Long-term course of symptomatic and asymptomatic middle cerebral artery stenosis. Neurology 1996; 46: 281.
39. Sliwka U, Klötzsch C, Popescu O, Brandt K, Berlit P, Noth J. Anticoagulation versus antiaggregation in patients with middle cerebral artery stenosis. Cerebrovasc Dis 1996; 6 (Suppl 3): 3.
40. The Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Study Group. Prognosis of patients with symptomatic vertebral or basilar artery stenosis. Stroke 1998; 29: 1389-92.
41. The WASID Investigators. Best treatment for intracranial arterial stenosis? 50 years of uncertainty. Neurology 2000; 55: 465-6.
42. Mohr J, Thompson JLP, Lazar RM, Levin B, Sacco RL, Furie KL, et al, for the Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444-51.
43. Chimowitz MI. Angioplasty or stenting is not appropriate as first-line treatment of intracranial stenosis. Arch Neurol 2001; 58: 1690-2.